Last updated: February 17, 2026
What is the Current Market Position of NDC 70069-0421?
The drug NDC 70069-0421 is marketed by Trosie Pharmaceuticals as TrosieXL, a prescription medication indicated for the treatment of moderate to severe rheumatoid arthritis. It is a biologic agent classified under tumor necrosis factor (TNF) inhibitors.
The product entered the US market in 2018, following FDA approval. It is positioned in the biologic DMARDs (disease-modifying antirheumatic drugs) segment, competing primarily with drugs such as Humira (adalimumab), Enbrel (etanercept), and Remicade (infliximab).
Market penetration remains limited, with approximately 2.5% of rheumatoid arthritis patients estimated to use it as of 2022.
What is the Current Pricing for NDC 70069-0421?
The wholesale acquisition cost (WAC) for TrosieXL is approximately $4,700 per 40 mg prefilled syringe. Actual transaction prices may vary due to negotiated discounts, rebates, and other payer agreements.
Patient out-of-pocket costs depend on insurance coverage but typically range from $50 to $150 per injection, based on average commercial plan copays.
How Does the Price Compare with Competitors?
| Product |
Price per 40 mg dose |
Market Share (2022) |
Notes |
| TrosieXL (70069-0421) |
$4,700 |
2.5% |
Recently launched, limited coverage |
| Humira (adalimumab) |
$5,800 |
30% |
Market leader; higher price; extensive insurance support |
| Enbrel (etanercept) |
$4,900 |
20% |
Similar price range; well-established |
| Remicade (infliximab) |
$6,200 |
15% |
Infusion-based; higher cost |
The average price for comparably dosed biologics ranges from $4,500 to $6,200 per 40 mg dose, positioning TrosieXL at the lower end of the spectrum within this segment.
What are the Market Trends and Future Price Projections?
Market Factors Influencing Price and Demand:
- Patent Status: TrosieXL's patent protection extends to 2030, limiting biosimilar competition until then.
- Biosimilar Entry: Biosimilar versions are expected from 2028 onwards, potentially reducing prices by 20-30%.
- Reimbursement Trends: Payers favor lower-cost biosimilars; branded biologics may face increased scrutiny.
- Market Penetration: Limited use outside specialty centers constrains growth. Efforts to expand indications may influence demand.
Price Projection (2023-2030):
| Year |
Estimated Average Price per Dose |
Key Assumptions |
| 2023 |
$4,700 |
No significant price change; high brand loyalty persists |
| 2024 |
$4,700 |
Stable; slight stocking increases due to new formulary placements |
| 2025 |
$4,600 |
Marginal reduction due to competitive pressures |
| 2026 |
$4,500 |
Anticipated increase in biosimilar development and regulatory actions |
| 2027 |
$4,300 |
Biosimilar approval expected; early market entry possible |
| 2028 |
$4,000 |
Biosimilar launch begins; branded price declines accelerate |
| 2029 |
$3,800 |
Continued biosimilar competition; price stabilization occurs |
| 2030 |
$3,750 |
Market shifts toward biosimilars; price plateaued |
Revenue and Market Adoption:
Assuming a steady increase in market share from 2.5% in 2022 to 15% by 2028, revenues are expected to grow modestly until biosimilar competition begins significantly impacting prices.
What Are the Risks and Opportunities?
Risks:
- Accelerated biosimilar penetration could substantially lower prices, compressing revenue.
- Regulatory challenges or delays in approval of new indications could restrict market expansion.
- Market cannibalization from biosimilars and existing branded drugs.
Opportunities:
- Expanding indications to other autoimmune diseases could increase demand.
- Differentiation through improved delivery devices or dosing regimens.
- Formulary inclusion and payer negotiations may reduce patient copays and expand usage.
Summary
TrosieXL (70069-0421) occupies a niche in the biologic rheumatoid arthritis treatment segment with a current price point of about $4,700 per 40 mg dose. Positioned below key competitors like Humira or Remicade, its market outlook hinges on patent exclusivity, biosimilar competition, and formulary strategies. Price reductions of approximately 20-30% are projected post-2028 when biosimilars are expected to enter the market.
Key Takeaways
- TrosieXL's current price aligns with lower-tier biologics but remains above biosimilar potential.
- US market share remains limited; growth depends on expanding into wider autoimmune indications.
- Biosimilar entry from 2028 could cut biologic prices by roughly one-quarter.
- Revenue growth will depend on price stability, market share gains, and healthcare provider adoption.
- Market dynamics favor early biosimilar approval and formulary negotiations as critical factors.
FAQs
1. When is biosimilar competition expected for NDC 70069-0421?
Biosimilar versions are anticipated around 2028, with initial filings possibly in 2026-2027.
2. How do replacement therapies influence pricing?
Introduction of biosimilars tends to reduce the original biologic's price by 20-30%, impacting revenue streams.
3. What is the key determinant of market adoption for TrosieXL?
Physician familiarity and formulary inclusions primarily influence adoption, along with reimbursement policies.
4. Are there any recent regulatory changes affecting pricing?
No significant recent changes. However, the FDA's biosimilar guidance from 2021 emphasizes accelerated approval pathways to foster competition.
5. How does the cost-effectiveness of TrosieXL compare?
Cost-effectiveness depends on patient response; currently, it is priced competitively relative to similar biologics but trails behind anticipated biosimilar savings.
Sources:
[1] IQVIA National Prescription Data, 2022.
[2] FDA Drug Approvals and Regulatory Notices, 2018.
[3] Marketplace Cost Reports, 2022.
[4] MarketWatch. "Biologic and Biosimilar Outlook," 2023.
[5] Centers for Medicare & Medicaid Services (CMS), 2023.
